Clinical Trial Update: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating subcutaneous immunoglobulin IgPro20 for chronic inflammatory demyelinating polyneuropathy has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy
• Polyradiculoneuropathy

Drugs mentioned

• IgPro20 (intravenous immunoglobulin 20% solution)

Snippet

Sponsor: CSL Behring | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy | Phase 3 | Status: COMPLETED | Results posted: 2018-07-05